OptiNose — Q2 2018 Earnings Presentation
18 slides from OptiNose's earnings presentation, Aug 14, 2018
Slide 1: Building a Leading ENT / Allergy Specialty Company
Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation A u g u s t 1 4 , 2 0 1 8
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Recent Key Accomplishments
Recent Key Accomplishments Executed contracts with two of the Publication of NAVIGATE II largest PBMs and EXHANCE-12 studies in in the US Peer-Reviewed Journals Physician Adoption Completed successful in ENT / Allergy $60M public offering Total Trialists in June 2018 CS trial design reviewed in meet
Slide 4: High Awareness Generated Rapid Trials of XHANCE
High Awareness Generated Rapid Trials of XHANCE Pre-Launch (1Q 2018) Early Launch (2Q 2018) Jan Feb Mar Apr May Jun DIGITAL, SOCIAL AND NON-PERSONAL PROMOTION Corporate Campaign CLINICAL NURSE EDUCATORS 87% Awareness Device + Deposition OPTINOSE SALES FORCE XPERIENCE 4
Slide 5: Encouraging Feedback From Xperience Patient Survey
Encouraging Feedback From Xperience Patient Survey Patient Responses Prior to Month 2 Refill Total Prior User of Prior User Respondents Flonase / Nasonex Budesonide Rinse (N=2,733) (n=820) (N=175) Patient Satisfaction 89% 90% 90% Experience Symptom Improvement 80% 79% 68% Prefer XHANCE 77% 82% 83% R
Slide 6: Early XHANCE Launch Accelerated by CNEs/Xperience
Early XHANCE Launch Accelerated by CNEs/Xperience (Week ending July 27, 2018) Cumulative Physician Trialists Device Deposition Data As of July 27, ~40% of 2,800 called physicians have 2,667 2,600 prescribed XHANCE 2,400 ▪ 2,200 94% brand / device awareness among ENT 2,000 and Allergists 1,800 ▪ 1,60
Slide 7: Examples of Positive XHANCE Physician Feedback
Examples of Positive XHANCE Physician Feedback * “I have a patient who has been advised for years that he had to have surgery. After treatment with XHANCE, he went to see his ENT and he was told he did not need surgery anymore.” - Allergist “I had a severe patient and my goal was for the patient’s “
Slide 8: XHANCE Commercial Market Access
XHANCE Commercial Market Access XHANCE Overall Access: July 2018 • Nationally, we believe 76% of commercial lives are currently in a plan where XHANCE is covered. 24% • We continue to focus on access with minimized hassle for 76% prescribers and patients. • We are working towards achieving “limited
Slide 9: Key Observations From the Initial Months of Launch
Key Observations From the Initial Months of Launch ▪ Our Clinical Nurse Educator initiative helped drive high awareness levels and created “pent up demand” prior to launch ▪ The Xperience program was effective at lowering barriers to pull- through of “pent up demand” and in helping drive initial tri
Slide 10: XHANCE Impacted by Seasonality Observed in INS Market
XHANCE Impacted by Seasonality Observed in INS Market Continued growth during strong seasonal decline Monthly TRxs for Monthly XHANCE and INS Market TRxs Intranasal Steroids (INS) for 2016-2018 (Through June 2018) Market (000s) XHANCE +8% Market (000s) 4,500 3,500 3,450 4,500 3,191 3,000 4,000 4,000
Slide 11: Sample Distribution Increased in June and July
Sample Distribution Increased in June and July XHANCE Sample Distribution for ▪ XHANCE samples contain 120 sprays Weeks ended May 5 through July 28 – the same as the bottle available by 1,600 prescription Patient support ▪ updated to include $0 Sampling volume increased in June 1,400 out of pocket f
Slide 12: XHANCE and INS Market Weekly TRx Demand in July
XHANCE and INS Market Weekly TRx Demand in July Includes Xperience Program and Retail Data XHANCE July Weekly TRX Demand ▪ (Through July 27, 2018) Total samples distributed in the last 3 weeks of July increased by XHANCE Market (M) ~2,000 relative to an average 3 1,000 800 weeks from May and June 90
Slide 13: Second Half 2018 Business Priorities
Second Half 2018 Business Priorities ▪ Continue to leverage rich data sets to maintain balance of discipline and flexibility in commercial execution ▪ Shift communication emphasis toward Xhance efficacy during calls with physicians and their staff - Promote additional registration data (eg, SNOT-22,
Slide 14: Financial Review – Second Quarter 2018
Financial Review – Second Quarter 2018 Q2 2018 Revenues and Average Selling Price (ASP) ▪ ($ 000’s) As planned, most units of XHANCE were $1,274 sold through the Xperience program in Q2 - As a reminder, Q1 revenues were primarily the result of building wholesale inventory $865 for the April 2018 ret
Slide 15: Financial Review – Third Quarter and Full Year 2018
Financial Review – Third Quarter and Full Year 2018 Q3 and Full Year 2018 Perspectives ▪ Operating Expenses now expected in the range from $117M to $121M for the full year of 2018 - Prior range was $119M to $125M ▪ We expect Q3 ASP to be similar to Q2 ASP due to the following factors: - A substantia
Slide 16: Chronic Sinusitis Supplemental Indication (sNDA)
Chronic Sinusitis Supplemental Indication (sNDA) Met with FDA Selection of CRO First patients regarding CS and study expected to study design locations enroll in 4Q 2018 Chronic Sinusitis trial design expected to include co-primary endpoints: both an objective measure of inflammation and a subjectiv
Slide 17: XHANCE
XHANCE’
Slide 18: Investor Relations
Investor Relations – NASDAQ: OPTN At 30 June 2018: Analyst Coverage1 – $245 million in cash – Long-term debt: $75 million BMO: Gary Nachman – 41.1 million common shares o/s Jefferies: David Steinberg – 8.0 million options & warrants o/s Cantor Fitzgerald: William Tanner Optinose Investor Contact Jon